Clinical Overview > Condition/ Syndrome > Quadrantanopia
You are looking at 1 - 2 of 2 items
Search for other papers by J Bukowczan in
Google Scholar
PubMed
Search for other papers by K Lois in
Google Scholar
PubMed
Search for other papers by M Mathiopoulou in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
Search for other papers by R A James in
Google Scholar
PubMed
Summary
Giant prolactinomas are rare tumours of the pituitary, which typically exceed 40 mm in their largest dimension. Impairment of higher cognitive function has been noted post-operatively after transcranial surgery and as a long-term consequence of the radiotherapy treatment. However, there has been little that is reported on such disturbances in relation to the tumour per se, and to our knowledge, there has been none in terms of responsivity to dopamine agonist therapy and shrinkage in these tumours. We present a case of successful restoration of severely impaired cognitive functions achieved safely after significant adenoma involution with medical treatment alone.
Learning points
-
Giant prolactinomas can be present with profound cognitive defects.
-
Dopamine agonists remain in the mainstay first-line treatment of giant prolactinomas.
-
Mechanisms of the reversible cognitive impairment associated with giant prolactinoma treatment appear to be complex and remain open to further studies.
-
Young patients with giant prolactinomas mandate genetic testing towards familial predisposition.
Search for other papers by Gabriela Alejandra Sosa in
Google Scholar
PubMed
Search for other papers by Soledad Bell in
Google Scholar
PubMed
Search for other papers by Silvia Beatriz Christiansen in
Google Scholar
PubMed
Search for other papers by Marcelo Pietrani in
Google Scholar
PubMed
Search for other papers by Mariela Glerean in
Google Scholar
PubMed
Search for other papers by Monica Loto in
Google Scholar
PubMed
Search for other papers by Soledad Lovazzano in
Google Scholar
PubMed
Search for other papers by Antonio Carrizo in
Google Scholar
PubMed
Search for other papers by Pablo Ajler in
Google Scholar
PubMed
Search for other papers by Patricia Fainstein Day in
Google Scholar
PubMed
Summary
IgG4-related hypophysitis is a recently described entity belonging to the group of IgG4-related diseases. Many other organs can also be affected, and it is more common in older men. To date, 32 cases of IgG4-related hypophysitis have been reported in the literature, 11 of which included confirmatory tissue biopsy and the majority affecting multiple organs. The aim of this report is to present two cases of biopsy-proven IgG4-related hypophysitis occurring in two young female patients with no evidence of involvement of other organs at the time of diagnosis.
Learning points
-
IgG4-related hypophysitis belongs to the group of IgG4-related diseases, and is a fibro-inflammatory condition characterized by dense lymphoplasmacytic infiltrates rich in IgG4-positive plasma cells and storiform fibrosis.
-
It is more common in older men, but young women may also present this type of hypophysitis.
-
Although involvement of other organs is frequent, isolated pituitary disease is possible.
-
Frequent clinical manifestations include anterior hypopituitarism and/or diabetes insipidus.
-
The diagnosis may be confirmed with any of the following criteria: a pituitary biopsy with lymphoplasmacytic infiltrates, with more than ten IgG4-positive cells; a sellar mass and/or thickened pituitary stalk and a biopsy-proven involvement of another organ; a sellar mass and/or thickened pituitary stalk and IgG4 serum levels >140 mg/dl and sellar mass reduction and symptom improvement after corticosteroid treatment.
-
Glucocorticoids are recommended as first-line therapy.
